These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1495828)

  • 21. Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infections.
    Hurdle JG; O'Neill AJ; Chopra I
    J Antimicrob Chemother; 2004 Aug; 54(2):549-52. PubMed ID: 15243028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis.
    McLaws F; Chopra I; O'Neill AJ
    J Antimicrob Chemother; 2008 May; 61(5):1040-3. PubMed ID: 18299637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fusidic acid as a potential antistaphylococcal agent.
    Nicholson J; Chew T; Smith S
    N Z Med J; 1999 Jul; 112(1091):261-2. PubMed ID: 10448991
    [No Abstract]   [Full Text] [Related]  

  • 25. [In vitro study of the cefamandole-fosfomycin combination against methicillin-resistant staphylococci].
    Fosse T; David MF; Duluc F; Darmusey D; Tamalet C; Toga B
    Pathol Biol (Paris); 1984 Jun; 32(5 Pt 2):528-31. PubMed ID: 6462742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Fantin B; Leclercq R; Duval J; Carbon C
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2466-9. PubMed ID: 8285635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.
    Ng J; Gosbell IB
    J Antimicrob Chemother; 2005 Jun; 55(6):1008-12. PubMed ID: 15845784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Methicillin resistant staphylococci].
    Afanas'eva TI
    Antibiot Khimioter; 1998; 43(6):29-31. PubMed ID: 9644532
    [No Abstract]   [Full Text] [Related]  

  • 29. In-vitro activity of fusidic acid against methicillin-resistant Staphylococcus aureus.
    Erdenizmenli M; Yapar N; Sengönül A; Yüce A; Cakir N; Yulug N
    J Chemother; 2004 Jun; 16(3):310-1. PubMed ID: 15330332
    [No Abstract]   [Full Text] [Related]  

  • 30. Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing.
    Mason BW; Howard AJ; Magee JT
    J Antimicrob Chemother; 2003 Apr; 51(4):1033-6. PubMed ID: 12654748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus.
    Wang JL; Tang HJ; Hsieh PH; Chiu FY; Chen YH; Chang MC; Huang CT; Liu CP; Lau YJ; Hwang KP; Ko WC; Wang CT; Liu CY; Liu CL; Hsueh PR
    Int J Antimicrob Agents; 2012 Aug; 40(2):103-7. PubMed ID: 22612900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality control of direct molecular diagnostics for methicillin-resistant Staphylococcus aureus.
    van Belkum A; Niesters HG; MacKay WG; van Leeuwen WB
    J Clin Microbiol; 2007 Aug; 45(8):2698-700. PubMed ID: 17581936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The bactericidal power of antibiotic combinations. Application in the treatment of osteo-articular infections due to Staphylococcus aureus (author's transl)].
    Sirot J; Lopitaux R; Cluzel R; Bussière JL; Rampon S
    Nouv Presse Med; 1978 Oct; 7(36):3217-22. PubMed ID: 733486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Outburst of fusidic acid resistant Staphylococcus aureus].
    Kanazaki H; Akiyama H; Kanamoto A; Abe Y; Yamada T; Arata J; Umemura S; Ikeda M
    Nihon Hifuka Gakkai Zasshi; 1989 Apr; 99(4):507-10. PubMed ID: 2614994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fusidic acid in bone and joint infections.
    Atkins B; Gottlieb T
    Int J Antimicrob Agents; 1999 Aug; 12 Suppl 2():S79-93. PubMed ID: 10528790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fusidic acid resistance in Staphylococcus aureus isolates.
    Brown EM; Thomas P
    Lancet; 2002 Mar; 359(9308):803. PubMed ID: 11888633
    [No Abstract]   [Full Text] [Related]  

  • 37. A fatal infection caused by methicillin-resistant Staphylococcus aureus acquiring resistance to gentamicin and fusidic acid during therapy.
    Amirak ID; Li AK; Williams RJ; Noone P
    J Infect; 1981 Mar; 3(1):50-8. PubMed ID: 6926536
    [No Abstract]   [Full Text] [Related]  

  • 38. Demonstration of in vitro antagonism between fusidic acid and quinolones.
    Ertek M; Yazgi H; Erol S; Altoparlak U
    J Int Med Res; 2002; 30(5):525-8. PubMed ID: 12449523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fusidic acid in staphylococcal bone and joint infection.
    Coombs RR
    J Antimicrob Chemother; 1990 Feb; 25 Suppl B():53-60. PubMed ID: 2179204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusidic acid resistance in community isolates of methicillin susceptible Staphylococcus aureus and the use of topical fusidic acid: a retrospective case-control study.
    Mason BW; Howard AJ
    Int J Antimicrob Agents; 2004 Mar; 23(3):300-3. PubMed ID: 15164973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.